GREY:ATBPF - Post by User
Comment by
MrMugsyon Feb 07, 2021 11:56am
258 Views
Post# 32495738
RE:RE:Slide 6 ...
RE:RE:Slide 6 ...Doccole wrote: I didn't see this on the slide. Thanks for pointing it out.
I couldn't agree with you more. I look at it a couples ways-
1. We have these other drugs, and it's open for deals- similar with what Knight did with 346.
2. Hey big pharma- this what we are doing, we are a stand-alone company and we don't need you.
3. Otena is on the block, and we are ready to exit and continuously add both value and deals with our other drugs.
4. Also brings color to institutional investors
i agree with CEO Dan about a buyout being hard. I imagine ATE has a ridiculous price tag on the company due to potential with other drugs. Is it possible to be bought out? For sure, is it more likely to take a piece? Probably. Will that piece lead to a buy out down the road...maybe, happens a lot.
Hope for a press release about AH/ATE soon.
Doccole ... keep in mind that Knight has the rights to the family of ATE's products (see Knight's pipeline on their website and the article I cut/pasted below) for the following countires ... Canada, Russia, Israel and Sub-Saharan Africa. They used to also have Romania but sold it back to ATE so it could be packaged with Acbel's geographies. So, the spreadsheet isn't even accurate as Knight belongs in all sections of that column for regional partners.
As a betting man, I would say Knight knows the potential here and will be willing to pay fairly for the rights in South America and Mexico. To pay fairly, ATE has to prove the value first because they're not willing to give anything else away. I also think a deal here would boost our stock price to a level where many doors can open ... combining entities, entering the NASDAQ and buying time for USA-Europe-Japan deal(s).
Just a thought ... as I've said on the Knight board ... I've never been able to guess Goodman's moves over the past 20 years, why would I be right this time? Unlikely that I'm right but possible.
----------
TORONTO, CANADA — (Nov 16, 2015) — Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQX: ATBPF), a commercial-stage healthcare company with a growing portfolio of innovative products targeting inflammatory and degenerative disorders, announced today the signing of an exclusive long-term license and distribution agreement with Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading Canadian specialty pharmaceutical company, for Antibe’s anti-inflammatory and pain drugs, ATB-346, ATB-352 and ATB-340, as well as the rights to other, future Antibe prescription drugs.